chrysin and Vascular-Diseases

chrysin has been researched along with Vascular-Diseases* in 1 studies

Other Studies

1 other study(ies) available for chrysin and Vascular-Diseases

Article	Year
Furoxan nitric oxide donor coupled chrysin derivatives: synthesis and vasculoprotection. Bioorganic & medicinal chemistry letters, 2011, Feb-15, Volume: 21, Issue:4 A series of furoxan-based nitric oxide-releasing chrysin derivatives were synthesized. Pharmacological assays indicated that all chrysin derivatives exhibited in vitro inhibitory activities against aldose reductase and advanced glycation end-product formation. Some chrysin derivatives were also found to increase the glucose consumption of HepG2 cells. Furthermore, the compounds released a low amount of NO in the presence of L-cysteine (range from 0.20% to 1.89%). These hybrid furoxan-based NO donor chrysin derivatives offer a mutual prodrug design concept for the development of therapeutic or preventive agents for vascular complications due to diabetes. Topics: Aldehyde Reductase; Cysteine; Flavonoids; Glycation End Products, Advanced; Hep G2 Cells; Humans; Nitric Oxide; Oxadiazoles; Vascular Diseases	2011

Article

Year

Furoxan nitric oxide donor coupled chrysin derivatives: synthesis and vasculoprotection.

Bioorganic & medicinal chemistry letters, 2011, Feb-15, Volume: 21, Issue:4

A series of furoxan-based nitric oxide-releasing chrysin derivatives were synthesized. Pharmacological assays indicated that all chrysin derivatives exhibited in vitro inhibitory activities against aldose reductase and advanced glycation end-product formation. Some chrysin derivatives were also found to increase the glucose consumption of HepG2 cells. Furthermore, the compounds released a low amount of NO in the presence of L-cysteine (range from 0.20% to 1.89%). These hybrid furoxan-based NO donor chrysin derivatives offer a mutual prodrug design concept for the development of therapeutic or preventive agents for vascular complications due to diabetes.

Topics: Aldehyde Reductase; Cysteine; Flavonoids; Glycation End Products, Advanced; Hep G2 Cells; Humans; Nitric Oxide; Oxadiazoles; Vascular Diseases

2011